

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. PENG Li (“**Mr. PENG**”) has been appointed as an executive Director and a member of the strategic committee of the Board, with effect from 25 July 2025.

Mr. PENG will enter into an employment agreement with the Company in relation to his appointment with effect from 25 July 2025, which shall automatically be effective hereafter. He shall hold office only until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election. Thereafter, Mr. PENG is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. The remuneration of Mr. PENG will be determined by the remuneration and evaluation committee of the Board with reference to his duties, market conditions and his time, effort, expertise and responsibilities to be devoted to the Group’s affairs and the Company’s remuneration policy. Currently, according to the Company’s remuneration policy, Mr. PENG will receive remuneration based on the performance appraisal, incentive measures and annual salary standard settlement.

The biography details of Mr. PENG are set out as below:

Mr. PENG Li, aged 53, chief physician, doctoral supervisor, graduated from rehabilitation medicine major of Tongji Medical College of Huazhong University of Science and Technology with a doctoral degree in June 2008. Mr. PENG has rich knowledge in traditional Chinese medicine. He actively promoted development of the discipline of traditional Chinese medicine during his tenure as physician and engaged in exchange at Trauma Center in Hamburg, Germany. Mr. PENG served as physician and director of the acupuncture department, the deputy party secretary and vice director of Taihe Hospital (Affiliated Hospital of Hubei University of Medicine); the party secretary and the director of Shiyuan Hospital of Traditional Chinese Medicine; and the party secretary, the chairman and level I

division rank official of Shiyan Health Commission. Since he joined China National Pharmaceutical Group Co., Ltd., Mr. PENG has served as the executive director of Institution of Sinopharm Medical Innovation, the chairman and the party secretary of Sinopharm Huazhong (Hubei) Healthcare Co., Ltd. and the party secretary of Sinopharm Dongfeng Hospital. Mr. PENG has served as the deputy party secretary of the Company since March 2025.

Save as disclosed above, Mr. PENG (i) does not hold any other position within the Group; (ii) has not held directorships in any other listed companies in the past three years; (iii) has not held any other major appointments and professional qualifications; and (iv) does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)).

As at the date of this announcement, Mr. PENG does not have any interest in the shares, underlying shares or debentures of the Company and/or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters concerning Mr. PENG that need to be brought to the attention of the shareholders of the Company, nor is there any information relating to Mr. PENG that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express welcome to Mr. PENG for his appointment as the executive Director.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
YANG Jun
Chairman

Hong Kong, 25 July 2025

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. YANG Jun, Mr. LI Hongjian and Mr. PENG Li are executive Directors; Mr. LIU Haijian, Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.